Microbiotica

📍 Cambridge, United Kingdom🗓 Founded 2016👥 49 employees💰 Last funded Mar 2022
Biotechnology Research🌐 microbiotica.com
Website LinkedIn
Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products. Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair. It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, Genentech/Roche in IBD, and University of Adelaide in Ulcerative Colitis.
3
Total investors
2
Early stage
0
Mid stage
1
Late stage
2016
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
3
Investor activity2016–2022 · investors recorded per year
201612017120221
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Microbiotica?
Microbiotica has 3 investors on record on gritt.io, including 2 early-stage backers and 1 late-stage investors.
When did Microbiotica last raise funding?
The most recent investment in Microbiotica recorded on gritt.io was in March 2022.
When was Microbiotica founded?
Microbiotica was founded in 2016.
What industry is Microbiotica in?
Microbiotica operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Microbiotica based?
Microbiotica is headquartered in Cambridge, United Kingdom.